UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
July 9, 2015
(Date of Report - date of earliest event reported)
Tekmira Pharmaceuticals Corporation
(Exact Name of Registrant as Specified in Its Charter)
|
British Columbia, Canada
(State or Other Jurisdiction of
Incorporation or Organization)
|
001-34949
(Commission File Number)
|
98-0597776
(I.R.S. Employer
Identification No.)
|
|
100-8900 Glenlyon Parkway
Burnaby, British Columbia, Canada
(Address of Principal Executive Offices)
|
V5J 5J8
(Zip Code)
|
(604) 419-3200
(Registrant's Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
□ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
□ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
□ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
□ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.07. Submission of Matters to a Vote of Security Holders.
On July 9, 2015, Tekmira Pharmaceuticals Corporation (the “Corporation”) held its Annual General and Special Meeting of Shareholders. At the meeting, shareholders voted in favor of all items of business, as indicated below:
Proposal 1. The Corporation’s shareholders voted to elect the following persons to the board of directors of the Corporation:
|
Nominee
|
Votes For
|
% For
|
Votes Withheld
|
% Withheld
|
Abstentions
|
Broker Non-Votes
|
|
Vivek Ramaswamy
|
26,370,119
|
99.75
|
65,181
|
0.25
|
0
|
7,833,906
|
|
Herbert J. Conrad
|
26,398,887
|
99.86
|
36,413
|
0.14
|
0
|
7,833,906
|
|
Richard C. Henreques
|
26,382,492
|
99.80
|
52,808
|
0.20
|
0
|
7,833,906
|
|
Frank Karbe
|
25,311,812
|
95.75
|
1,123,488
|
4.25
|
0
|
7,833,906
|
|
Keith Manchester
|
26,379,463
|
99.79
|
55,837
|
0.21
|
0
|
7,833,906
|
|
William T. Symonds
|
26,386,617
|
99.82
|
48,683
|
0.18
|
0
|
7,833,906
|
|
Mark J. Murray
|
26,344,932
|
99.66
|
90,368
|
0.34
|
0
|
7,833,906
|
Proposal 2. The Corporation’s shareholders voted to appoint KPMG LLP as auditor of the Corporation for the ensuing year:
|
Votes For
|
% For
|
Votes Withheld
|
% Withheld
|
Abstentions
|
Broker Non-Votes
|
|
34,095,774
|
99.49
|
173,432
|
0.51
|
0
|
0
|
Proposal 3. The Corporation’s shareholders voted to authorize an amendment of the Corporation’s omnibus share compensation plan to increase, by 3,500,000 common shares, the number of common shares in respect of which awards may be granted thereunder:
|
Votes For
|
% For
|
Votes Against
|
% Against
|
Abstentions
|
Broker Non-Votes
|
|
21,669,574
|
81.83
|
4,812,573
|
18.17
|
0
|
7,833,906
|
Proposal 4. The Corporation’s shareholders voted to authorize an amendment of the Corporation’s Articles setting the quorum for the transaction of business at a meeting of shareholders as the presence in person or by proxy, of the holders of at least 33 1/3% of the issued and outstanding common shares of the Corporation:
|
Votes For
|
% For
|
Votes Against
|
% Against
|
Abstentions
|
Broker Non-Votes
|
|
26,356,621
|
99.70
|
78,679
|
0.30
|
0
|
7,833,906
|
Proposal 5. The Corporation’s shareholders voted to approve, on an advisory basis, the Corporation’s named executive officer compensation:
|
Votes For
|
% For
|
Votes Against
|
% Against
|
Abstentions
|
Broker Non-Votes
|
|
26,306,594
|
99.51
|
128,706
|
0.49
|
0
|
7,833,906
|
Proposal 6. The Corporation’s shareholders voted to approve, on an advisory basis, that three years be the frequency in which an advisory vote on named executive officer compensation should be held, with the votes breaking down as follows:
|
Frequency of Vote
|
Votes For
|
% For
|
|
|
1 Year
|
7,539,370
|
28.63
|
|
|
2 Years
|
121,817
|
0.46
|
|
|
3 Years
|
18,675,726
|
70.91
|
|
|
Broker-Non Votes
|
7,979,140
|
||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: July 14, 2015
|
TEKMIRA PHARMACEUTICALS CORPORATION
|
|||
|
By:
|
/s/ Bruce Cousins
|
||
|
Name: Bruce Cousins
Title: Executive Vice President & Chief Financial Officer
|
|||